| Company Name: | Allscripts Healthcare Solutions Inc | | Ticker Symbol: | MDRX | | | WWW Address: | www.allscripts.com |
| CEO: | Paul M. Black | | No. of Employees: | 7,100 |
| Common Issue Type: | CS | | Business Description: | Allscripts Healthcare Solutions Inc is a provider of clinical, financial, connectivity and information solutions and related professional services that empower hospitals, physicians and post-acute organizations to deliver world-class outcomes.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 13.38 |  0.05 | 13.22 | 13.55 | 13.36 | 13.26 | 13.00 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,371.8 | 177.3 | 1.27 | -0.01 | 0.00 | 0.0 | 0.0 | 14.24 - 8.84 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 13.25 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 2,371.8 | mil |
| Latest Shares Outstanding | 177.3 | mil |
| Earnings pS (EPS) | -0.01 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 203,708 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 176.8 | mil |
| Float as % of Shares Outstanding | 99.9 | % |
| Foreign Sales | 59 | mil |
| Domestic Sales | 1,387 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 27.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 12.40 | % |
| Gross Profit Margin | 49.5 | % |
| EBITDA Margin | 9.7 | % |
| Pre-Tax Profit Margin | -3.6 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | -0.5 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -0.7 | % |
| Current Ratio | 1.0 | |
| Leverage Ratio (Assets/Equity) | 2.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.41 | |
| LT Debt/Total Capital | 26.0 | % |
| Working Capital pS | -0.05 | $ |
| Cash pS | 0.52 | $ |
| Book-Value pS | 7.53 | $ |
| Tangible Book-Value pS | -2.03 | $ |
| Cash Flow pS | 0.81 | $ |
| Free Cash Flow pS | -0.43 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 1.76 | |
| Price/Tangible Book Ratio | -6.53 | |
| Price/Cash Flow | 16.4 | |
| Price/Free Cash Flow | -30.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.4 | 97 | 29,096 | 197,082 |
| 4 Weeks | 14.15 | 13.00 | 14.09 | -6.0 | 96 | 23,942 | 430,950 |
| 13 Weeks | 14.24 | 12.36 | 13.81 | -4.1 | 92 | 21,132 | 1,310,161 |
| 26 Weeks | 14.24 | 8.85 | 10.78 | 22.9 | 106 | 30,217 | 3,716,740 |
| 52 Weeks | 14.24 | 8.84 | 10.90 | 21.6 | 100 | 31,781 | 7,881,712 |
| YTD | 14.24 | 9.25 | - | 40.7 | 123 | 26,238 | 2,964,843 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 13.53 | 13.56 | 13.51 | 12.18 | 12.17 | 1.27 | 1.02 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 33.14 | 85.6 | 35.50 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 0.00 |
| R&D | 0.00 | NA | 54.32 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -4.8 | -4.8 | 0.2 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | -100.0 | -100.0 | -100.0 |
| EPS $ | -0.10 | -0.10 | -0.40 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 2.28 |
| Current Ratio | 1.1 |
| Quick Ratio (Acid Test) | 0.8 |
| Liquidity Ratio (Cash) | 0.19 |
| Receivables Turnover | 4.1 |
| Average Collection Period | 88 |
| Working Capital/Equity | 4.2 |
| Working Capital pS | 0.32 |
| Cash-Flow pS | 0.86 |
| Free Cash-Flow pS | 0.58 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 1.91 |
| Financial Leverage Ratio (Assets/Equity) | 1.9 |
| Debt Ratio | 46.1 |
| Total Debt/Equity (Gearing Ratio) | 0.34 |
| LT Debt/Equity | 0.28 |
| LT Debt/Capital Invested | 33.2 |
| LT Debt/Total Liabilities | 33.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.88 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 18.21 |
| Tobin's Q Ratio | 0.99 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | 19.16 |
| Enterprise Value (EV)/Free Cash Flow | 37.08 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -6.53 |
| Price/Book Ratio - LTM | 1.76 |
| Price/Cash Flow Ratio | 16.4 |
| Price/Free Cash Flow Ratio - LTM | -30.9 |
| Price/Sales Ratio | 1.64 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 43.1 |
| P/E Ratio (52 weeks ago) - LTM | 31.1 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 2.10 |
| Current Liabilities pS | 3.21 |
| Tangible Book Value pS - LTM | -2.03 |
| Book Value pS - LTM | 7.53 |
| Capital Invested pS | 9.29 |
| Cash pS - LTM | 0.52 |
| Cash Flow pS - LTM | 0.81 |
| Free Cash Flow pS - LTM | -0.43 |
| Earnings pS (EPS) | -0.01 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 6.88 |
| Free Cash Flow Margin 5YEAR AVG | 3.93 |
| Net Profit Margin | -0.1 |
| Net Profit Margin - 5YEAR AVRG. | 0.4 |
| Equity Productivity | 1.13 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.3 |
| Capital Invested Productivity | 0.88 |
| Return on Capital Invested (ROCI) | -0.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.3 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 0.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.2 |
| Gross Profit Margin | 49.5 |
| Gross Profit Margin - 5YEAR AVRG. | 53.3 |
| EBITDA Margin - LTM | 9.7 |
| EBIT Margin - LTM | -2.4 |
| Pre-Tax Profit Margin | -1.2 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 5.2 |
| Effective Tax Rate | 93.4 |
| Effective Tax Rate - 5YEAR AVRG. | 24.7 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 85 |
| Revenue per Employee | 203,708 |
| Net Income per Employee | -162 |
| Average Collection Period | 84 |
| Receivables Turnover | 4.1 |
| Day's Inventory Turnover Ratio | 1 |
| Inventory Turnover | 704.4 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 3.17 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 26.56 |
| Fixed Assets Turnover | 0.81 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 13.91 |
| Revenue per $ Plant | 9.30 |
| Revenue per $ Common Equity | 1.13 |
| Revenue per $ Capital Invested | 0.88 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 30.1 |
| Research & Devlopment (R&D) as % of Revenue | 11.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 11.2 |
|
|  
|
| |
 |  |
